ATRC Healthcare

AtriCure, Inc.

$60.41+0.89%

Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026

Basics

Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States
Market cap: 3.1B USD
Enterprise value: 2.7B USD
Full-time employees: 1,350

Overall health

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 1.25 vs a peer median of 0.63)bigger price swings (beta 1.25 vs peers 0.63)
About average: profitability and risk (debt, liquidity and share-price swings)profitability and risk

Ranks #552 of 1,157 healthcare companies (top 48%)

See how it ranks against its peers

Worth knowing

Earnings turned from a loss to a profit. Profit per share this year after a loss last year.
AtriCure made a profit per share in its latest year after a loss the year before.
Cash flow well above reported profit. Free cash flow is 5.0× reported profit.
Free cash flow is 5.0× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.
Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $207M in 2020 to $535M in 2025.
AtriCure's fiscal-year revenue rose in each of the five years to 2025, from $207M to $535M.

StockQuotient Score

53/ 100

Oct 5 54 → Nov 4 53 (-1)

Valuation

Is the price right?

36/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield0.3%

SEC filings · 12 months to Jun 2026Reported value30% base weight · Z-score -0.77Sector median: 0.0148 · MAD: 0.0148

EBITDA yield1.1%

SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score -0.72Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield1.7%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield16.8%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

83/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 3.2%

Why

Stronger than most peers on:

▲ EPS growth
▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a loss to a profit33% base weight · Z-score 4.46Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth15.9%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 1.20Sector median: 0.0584 · MAD: 0.0840

Revenue growth13.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.80Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

42/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Turned profitable over the last 12 months
Operating margin rose 2.8 points to 2.3%

Why

Held back by:

▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin2.3%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.39Sector median: 0.0706 · MAD: 0.1217

Return on assets1.6%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.02Sector median: 0.0166 · MAD: 0.0537

Return on invested capital2.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.22Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin76.3%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity2.0%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Mixed versus peers:

▲ Current ratio
▲ Debt / equity
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.25

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.85Sector median: 0.6250 · MAD: 0.3380

Current ratio4.22×

SEC filings · latest balance sheetReported value33% base weight · Z-score 1.18Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.12×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.51Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about AtriCure

Is AtriCure getting weaker?: Its latest SEC filing (Jul 27, 2026) got stronger: turned profitable over the last 12 months; operating margin rose 2.8 points to 2.3%. Its overall score is unchanged at 53/100 since Oct 28, 2026.
How is AtriCure valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 36/100 against 1,393 healthcare peers. EBITDA yield 1.1% vs a peer median of 4.0% (weaker than 64% of peers).EBITDA yield 1.1% vs peers 4.0% (weaker than 64% of peers).
Is AtriCure growing?: Yes, faster than most of its peers. Growth scores 83/100 against 1,393 healthcare peers. 3-year revenue growth 15.9% vs a peer median of 5.8% (stronger than 75% of peers).3-year revenue growth 15.9% vs peers 5.8% (stronger than 75% of peers).
How profitable is AtriCure?: About as profitable as its peers. Profitability scores 42/100 against 1,393 healthcare peers. Operating margin 2.3% vs a peer median of 7.1% (weaker than 63% of peers).Operating margin 2.3% vs peers 7.1% (weaker than 63% of peers).
How risky is AtriCure?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 4.22× vs a peer median of 2.59× (stronger than 68% of peers).Current ratio 4.22× vs peers 2.59× (stronger than 68% of peers). Beta 1.25 vs a peer median of 0.63 (weaker than 82% of peers).Beta 1.25 vs peers 0.63 (weaker than 82% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Jul 27, 2026 · compared with the quarter ended Mar 31, 2026

Got stronger

Turned profitable over the last 12 months
Operating margin rose 2.8 points to 2.3%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	552.2M USD	569.6M USD	+3.2%
Net income (12 months)	−4.6M USD	10.6M USD	turned positive
Operating margin	-0.5%	2.3%	+2.8 pts
Free cash flow (12 months)	53.6M USD	53.1M USD	−1.0%
Debt	61.0M USD	61.0M USD	0.0%
Cash	146.2M USD	167.8M USD	+14.8%
Shares outstanding	50.6M	50.9M	+0.4%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Instruments & Supplies · 25 companies

Valuations in Medical Instruments & Supplies are near the bottom of their range since Jul 2018.

18% of months since Jul 2018 were valued lower than now.
0% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +17% vs the whole market, against a usual +86%.

Jul 2018Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	75.0%	74.4%	75.2%	74.7%	75.0%	▲ 0.3 pts
Operating margin	20.1%	-12.9%	-6.7%	-8.6%	-1.8%	▲ 6.8 pts
Net margin	18.3%	-14.1%	-7.6%	-9.6%	-2.1%	▲ 7.5 pts
Return on assets (ROA)	8.2%	-7.9%	-5.0%	-7.3%	-1.7%	▲ 5.6 pts
Return on equity (ROE)	10.4%	-10.2%	-6.5%	-9.7%	-2.3%	▲ 7.4 pts
Free cash flow margin	-8.6%	-11.8%	-1.9%	0.2%	9.0%	▲ 8.9 pts
Current ratio	3.47×	3.69×	3.57×	3.65×	3.96×	▲ 8.5%
Quick ratio	2.78×	2.90×	2.66×	2.62×	2.99×	▲ 14%
Debt to equity	0.12×	0.14×	0.14×	0.14×	0.13×	▼ 10%
Interest coverage	11.23×	-8.56×	-3.85×	-6.25×	-1.61×	▲ 74%

ATRC price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 1.25 vs a peer median of 0.63)bigger price swings (beta 1.25 vs peers 0.63)

About average: profitability and risk (debt, liquidity and share-price swings)profitability and risk

Ranks #552 of 1,157 healthcare companies (top 48%)

See how it ranks against its peers

Worth knowing

Earnings turned from a loss to a profit. Profit per share this year after a loss last year.

AtriCure made a profit per share in its latest year after a loss the year before.

Cash flow well above reported profit. Free cash flow is 5.0× reported profit.

Free cash flow is 5.0× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.

Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $207M in 2020 to $535M in 2025.

AtriCure's fiscal-year revenue rose in each of the five years to 2025, from $207M to $535M.

Questions investors ask about AtriCure

Is AtriCure getting weaker?

Its latest SEC filing (Jul 27, 2026) got stronger: turned profitable over the last 12 months; operating margin rose 2.8 points to 2.3%. Its overall score is unchanged at 53/100 since Oct 28, 2026.

How is AtriCure valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 36/100 against 1,393 healthcare peers. EBITDA yield 1.1% vs a peer median of 4.0% (weaker than 64% of peers).EBITDA yield 1.1% vs peers 4.0% (weaker than 64% of peers).

Is AtriCure growing?

Yes, faster than most of its peers. Growth scores 83/100 against 1,393 healthcare peers. 3-year revenue growth 15.9% vs a peer median of 5.8% (stronger than 75% of peers).3-year revenue growth 15.9% vs peers 5.8% (stronger than 75% of peers).

How profitable is AtriCure?

About as profitable as its peers. Profitability scores 42/100 against 1,393 healthcare peers. Operating margin 2.3% vs a peer median of 7.1% (weaker than 63% of peers).Operating margin 2.3% vs peers 7.1% (weaker than 63% of peers).

How risky is AtriCure?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 4.22× vs a peer median of 2.59× (stronger than 68% of peers).Current ratio 4.22× vs peers 2.59× (stronger than 68% of peers). Beta 1.25 vs a peer median of 0.63 (weaker than 82% of peers).Beta 1.25 vs peers 0.63 (weaker than 82% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

552.2M USD

569.6M USD

+3.2%

Net income (12 months)

−4.6M USD

10.6M USD

turned positive

Operating margin

-0.5%

2.3%

+2.8 pts

Free cash flow (12 months)

53.6M USD

53.1M USD

−1.0%

Debt

61.0M USD

61.0M USD

0.0%

Cash

146.2M USD

167.8M USD

+14.8%

Shares outstanding

50.6M

50.9M

+0.4%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

75.0%

74.4%

75.2%

74.7%

75.0%

▲ 0.3 pts

Operating margin

20.1%

-12.9%

-6.7%

-8.6%

-1.8%

▲ 6.8 pts

Net margin

18.3%

-14.1%

-7.6%

-9.6%

-2.1%

▲ 7.5 pts

Return on assets (ROA)

8.2%

-7.9%

-5.0%

-7.3%

-1.7%

▲ 5.6 pts

Return on equity (ROE)

10.4%

-10.2%

-6.5%

-9.7%

-2.3%

▲ 7.4 pts

Free cash flow margin

-8.6%

-11.8%

-1.9%

0.2%

9.0%

▲ 8.9 pts

Current ratio

3.47×

3.69×

3.57×

3.65×

3.96×

▲ 8.5%

Quick ratio

2.78×

2.90×

2.66×

2.62×

2.99×

▲ 14%

Debt to equity

0.12×

0.14×

0.13×

▼ 10%

Interest coverage

11.23×

-8.56×

-3.85×

-6.25×

-1.61×

▲ 74%